Cargando…

848. Trends of Carbapenem Resistance in Enterobacterales in the US Between 2015 and 2019

BACKGROUND: Carbapenem-resistant Enterobacterales (CRE) are considered an urgent threat to human health by the CDC. Tracking resistance over time is of importance to understand trends and patterns. Tracking carbapenem resistance is complicated by definitions which include resistance to ertapenem onl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marcella, Stephen, Kanakamedala, Hemanth, Zhou, Yun, Cai, Bin, Pogue, Jason M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777407/ http://dx.doi.org/10.1093/ofid/ofaa439.1037

Ejemplares similares

842. Impact of Active Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections in US Hospitals Between 2014 and 2019
por: Pogue, Jason M, et al.
Publicado: (2020)

551. Burden of Illness in Carbapenem-Resistant Acinetobacter baumannii Infections in US Hospitals (2014 to 2018)
por: Pogue, Jason M, et al.
Publicado: (2019)

Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019
por: Pogue, Jason M., et al.
Publicado: (2022)

1458. Burden of Illness in Patients with Urinary Tract Infections With or Without Bacteremia Caused by Carbapenem-Resistant Gram-Negative Pathogens in US Hospitals (2014 to 2018)
por: Shields, Ryan K, et al.
Publicado: (2019)

1928. Trends In Incidence of Carbapenem-Resistant Enterobacterales (CRE) In Seven US sites, 2016─2020
por: Duffy, Nadezhda, et al.
Publicado: (2023)

Burden of illness in US hospitals due to carbapenem-resistant Gram-negative urinary tract infections in patients with or without bacteraemia
por: Shields, Ryan K., et al.
Publicado: (2021)

1443. Activity of Ceftazidime-Avibactam against Carbapemenase-negative Carbapenem-resistant Enterobacterales (CRE) Isolates from US Hospitals
por: Castanheira, Mariana, et al.
Publicado: (2020)

1218. Activity of Meropenem-Vaborbactam and Comparator Agents Against Carbapenemase-Negative, Carbapenem-Resistant Enterobacterales from US Hospitals
por: Castanheira, Mariana, et al.
Publicado: (2021)

2550. Comparing Efficacy of Serum and Epithelial Lining Fluid Concentrations for Meropenem Against Carbapenem-Resistant Enterobacterales
por: Lavoie, Thomas, et al.
Publicado: (2023)

164. Analysis of Adult, Hospitalized Patients With Carbapenem-resistant (CR) Gram-Negative Bloodstream Infections (GN-BSIs) due to Lactose Fermenters (LFs) and Non-lactose Fermenters (NLFs): Is There a Difference in Outcomes?
por: Lodise, Thomas, et al.
Publicado: (2019)

642. Facility Reported vs. CLSI MIC Breakpoint Comparison of Carbapenem Non-susceptible (Carb-NS) Enterobacteriaceae (ENT) from 2016-2019: A Multicenter Evaluation
por: Gupta, Vikas, et al.
Publicado: (2021)

786. Facility Reported vs. CLSI MIC Breakpoint Comparison of Carbapenem Non-susceptible (Carb-NS) Pseudomonas aeruginosa (PSA) From 2016-2019: A Multicenter Evaluation
por: Gupta, Vikas, et al.
Publicado: (2021)

733. Carbapenem-Resistant Enterobacterales (CRE) Colonization Prevalence in Botswana: an Antibiotic Resistance in Communities and Hospitals (ARCH) Study
por: Mannathoko, Naledi, et al.
Publicado: (2021)

416. Evaluating Indwelling Devices and Mortality in Invasive Carbapenem-Resistant Enterobacterales Infections, Atlanta, GA, 2012–2019.
por: Witt, Lucy S, et al.
Publicado: (2022)

1374. Carbapenem-Resistant Enterobacterales Infection in Children: Clinical and Molecular Data from a Prospective Multicenter Cohort Study
por: Fisher, Matthew, et al.
Publicado: (2020)

787. Clinical and Genomic Epidemiology of mcr-9 Containing Carbapenem-resistant Enterobacterales Isolates in Metropolitan Atlanta, 2012-2017
por: Babiker, Ahmed, et al.
Publicado: (2021)

2163. Risk Factors for Carbapenem-Resistant Gram-Negative Bloodstream Infections (BSI) in U.S. Hospitals (2010–2015)
por: Cai, Bin, et al.
Publicado: (2018)

1252. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales from Patients with Bloodstream Infections collected during the ATLAS Global Surveillance Program, 2015-2019
por: Lob, Sibylle, et al.
Publicado: (2021)

1576. Re-Evaluation of cefepime or piperacillin-tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales BloodStream Infections (REDUCE-BSI)
por: Vu, Catherine H, et al.
Publicado: (2020)

1257. Re-Evaluation of Cefepime or Piperacillin-Tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales Urinary Tract Infections (REDUCE-UTI)
por: Branton, Alexander C, et al.
Publicado: (2021)

1617. Mecillinam susceptibility against Enterobacterales isolated from urinary tract infections from US patients in 2018
por: Hawser, Stephen, et al.
Publicado: (2020)

716. Effect of Carbapenem-resistant vs. Carbapenem-susceptible Enterobacterales infections on patient outcomes at an academic medical center
por: Clark, Justin A, et al.
Publicado: (2023)

Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales
por: Kaye, Keith S., et al.
Publicado: (2023)

2749. Impact of rapid carbapenemase identification on management of patients with carbapenem-resistant Enterobacterales infections
por: Burke, Elysia, et al.
Publicado: (2023)

2152. Activity of Imipenem/Relebactam Against Carbapenem-Resistant Non-Morganellaceae Enterobacterales (NME) in the United States – SMART 2019-2021
por: Lob, Sibylle, et al.
Publicado: (2023)

1029. Increased Mortality in Hospital-Onset Carbapenem-Resistant Enterobacterales Bloodstream Infections
por: Boutzoukas, Angelique E, et al.
Publicado: (2023)

216. Association Between Days to Initiate Appropriate Therapy and Hospital Length of Stay Among Adult Hospitalized Patients With Gram-negative Bloodstream Infections (GN-BSI)
por: Lodise, Thomas, et al.
Publicado: (2019)

2477. Characteristics of patients infected with Carbapenem-resistant Acinetobacter baumannii complex and Carbapenem-resistant Enterobacterales in Tennessee, 2016–2021
por: Patel, Dipen, et al.
Publicado: (2023)

1043. Activity of Mecillinam Against Enterobacterales Isolates Collected From Patients With Urinary Tract Infections (UTIs) in the USA During 2019
por: Hawser, Stephen, et al.
Publicado: (2021)

1191. Prevalence and Microbiology of Carbapenem Resistance Among Six Gram-Negative Pathogens in Bloodstream Infections in US Hospitals, 2010–2015
por: Lodise, Thomas P, et al.
Publicado: (2018)

588. Ceftolozane/Tazobactam Susceptibility of Carbapenem-Resistant Pseudomonas aeruginosa and Carbapenem-Resistant Enterobacterales Isolates in a Tertiary Hospital in Korea
por: Kim, Kye-Hyung, et al.
Publicado: (2023)

Epidemiology of carbapenem-resistant and carbapenemase-producing Enterobacterales in the Netherlands 2017–2019
por: Wielders, Cornelia C. H., et al.
Publicado: (2022)

1621. Novel Beta-lactam Beta-lactamase Inhibitors Against Alternative Antibiotics for the Treatment of Complicated Urinary Tract Infections and Pyelonephritis Caused by Carbapenem-resistant Enterobacterales
por: Green, Bliss, et al.
Publicado: (2020)

1945. Antibacterial activity of cefepime/enmetazobactam and comparator agents against U.S. Enterobacterales clinical isolates collected from 2019-2021
por: Belley, Adam, et al.
Publicado: (2023)

158. Intra- and Inter-hospital Epidemiology of Carbapenem-resistant klebsiella Pneumoniae in US Hospitals
por: Luterbach, Courtney, et al.
Publicado: (2020)

P848: EXPRESSION PROFILE OF BCL-2 FAMILY PROTEINS IN MULTIPLE MYELOMA.
por: Sánchez, Cristina De Ramón, et al.
Publicado: (2023)

664. Increase in the Occurrence of Carbapenem-Resistant Enterobacterales (CRE) in United States (US) Hospitals from 2019 to 2021 and Activity of Novel b-Lactam/b-Lactamase Inhibitor (BL/BLI) Combinations Against These Isolates
por: Castanheira, Mariana, et al.
Publicado: (2022)

1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales
por: Ying, Yun, et al.
Publicado: (2020)

647. Cefepime Versus Carbapenems for the Treatment of ESBL-producing Enterobacterales among Non-blood Isolates
por: Garcia, Brandon, et al.
Publicado: (2022)

2779. Early Administration of Ceftazidime-Avibactam for Carbapenem-Resistant Enterobacterales Is Associated with Improved Clinical Success
por: Coyne, Ashlan J Kunz, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dt1cc404sqecilfs81sv6e2ed8